Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 948 2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

uptrend2025 May. 13 at 3:30 PM

$KAPA Someone could not handle the pressure and dumped their shares. I am holding and adding.

0 · Reply

GIPARK May. 13 at 1:45 PM

$KAPA $2

0 · Reply

focafoca99 May. 13 at 9:50 AM

$KAPA will present at the LD Micro Invitational XVI on May 18.

0 · Reply

newsfile_corp May. 13 at 9:31 AM

https://nfne.ws/297159 $KAPA #InvitationalXVI #ldmicro #Publishing #Investing

0 · Reply

DipBuyInvester May. 12 at 9:54 PM

$KAPA As of now: RSI: 8.33, MACD: -0.0217 Vol: 0.05, MA20: 0.59, MA50: 0.60 RSI (Relative Strength Index): 8.33 • The Signal: Extreme Oversold . MACD: -0.0217 • The Signal: Negative Momentum. . Moving Averages (MA20: 0.59 vs. MA50: 0.60) • The Signal: Bearish Alignment

0 · Reply

OfficialStocktwitsUser May. 12 at 9:48 PM

$KAPA RSI: 8.33, MACD: -0.0217 Vol: 0.05, MA20: 0.59, MA50: 0.60 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

uptrend2025 May. 12 at 2:39 PM

$KAPA Smells like spoofing walls on the ask. When you try to buy them, they disappear

1 · Reply

TraderBuckNKY May. 12 at 2:11 PM

$KAPA ..their going to let this bleed out...Dr. John S. Yu M.D., Ph.D. CEO/Chairman & Secretary - Mr. Douglas W. Samuelson CPA Chief Financial Officer - Dr. Neil A. Bhowmick Ph.D. Chief Scientific Officer - Dr. Ramachandran Murali Ph.D. Vice President of Research & Development ... ? any chance some of these guys are being pursued by ICE...? Why else would they let this happen...?

0 · Reply

joaneegell May. 12 at 1:50 PM

$KAPA stupidest decision i ever made was to believe in this POS company

0 · Reply

Oldshoe May. 11 at 9:39 PM

$KAPA My 200k plus shares are long term bullish. Certainly plan to vote yes for r/s. Plan to vote no for increasing executive compensation.

2 · Reply

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

May 8, 2026, 4:30 PM EDT - 4 days ago

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

Apr 15, 2026, 9:00 AM EDT - 4 weeks ago

Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

2026-03-02T11:53:03.000Z - 2 months ago

Kairos Pharma to acquire CL-273 from Celyn Therapeutics

Mar 2, 2026, 6:30 AM EST - 2 months ago

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

2026-02-26T14:24:59.000Z - 2 months ago

Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn

Feb 26, 2026, 7:00 AM EST - 2 months ago

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Jan 20, 2026, 8:00 AM EST - 4 months ago

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

2026-01-13T11:05:46.000Z - 4 months ago

Kairos Pharma files $75M mixed securities shelf

Dec 17, 2025, 8:15 AM EST - 5 months ago

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Nov 4, 2025, 8:00 AM EST - 6 months ago

Kairos Pharma Provides Shareholder Update

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Sep 18, 2025, 5:00 PM EDT - 8 months ago

Kairos Pharma Transcript: Study Update

2025-09-18T12:16:01.000Z - 8 months ago

Kairos Pharma announces interim efficacy analysis of ENV105

Sep 18, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 11, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Kairos Pharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:15 AM EDT - 9 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-04T14:05:21.000Z - 10 months ago

Kairos Pharma management to meet with Maxim

Jul 28, 2025, 12:28 PM EDT - 10 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 10 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

2025-07-16T01:26:00.000Z - 10 months ago

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

2025-07-15T13:15:24.000Z - 10 months ago

Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Provides Letter to Stockholders

2025-04-22T10:10:35.000Z - 1 year ago

Kairos Pharma files to sell 16.29M shares of common stock for holders

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

2025-04-03T10:16:23.000Z - 1 year ago

Kairos Pharma initiated with a Buy at H.C. Wainwright

2025-03-31T11:11:12.000Z - 1 year ago

Kairos Pharma completes safety lead-in of ENV105 trial

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

2025-03-27T11:40:11.000Z - 1 year ago

Kairos Pharma initiated with a Buy at Maxim

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

2025-02-26T12:27:01.000Z - 1 year ago

Kairos Pharma presents preclinical data on KROS 101, KROS 401

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

2025-02-18T13:42:31.000Z - 1 year ago

Kairos Pharma announces new DoD funding for ENV205 research

Feb 18, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

2025-02-11T13:36:20.000Z - 1 year ago

Kairos Pharma adds Huntsman Cancer Institute to Phase 2 ENV105 trial

Feb 11, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025

2025-01-14T15:00:26.000Z - 1 year ago

Kairos Pharma Ltd trading resumes

Jan 13, 2025, 2:00 PM EST - 1 year ago

Kairos Pharma Transcript: Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Kairos Pharma Transcript: 17th Annual LD Micro Main Event Conference

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 17, 2024, 1:00 PM EDT - 1 year ago

Kairos Pharma Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

uptrend2025 May. 13 at 3:30 PM

$KAPA Someone could not handle the pressure and dumped their shares. I am holding and adding.

0 · Reply

GIPARK May. 13 at 1:45 PM

$KAPA $2

0 · Reply

focafoca99 May. 13 at 9:50 AM

$KAPA will present at the LD Micro Invitational XVI on May 18.

0 · Reply

newsfile_corp May. 13 at 9:31 AM

https://nfne.ws/297159 $KAPA #InvitationalXVI #ldmicro #Publishing #Investing

0 · Reply

DipBuyInvester May. 12 at 9:54 PM

0 · Reply

OfficialStocktwitsUser May. 12 at 9:48 PM

0 · Reply

uptrend2025 May. 12 at 2:39 PM

$KAPA Smells like spoofing walls on the ask. When you try to buy them, they disappear

1 · Reply

TraderBuckNKY May. 12 at 2:11 PM

0 · Reply

joaneegell May. 12 at 1:50 PM

$KAPA stupidest decision i ever made was to believe in this POS company

0 · Reply

Oldshoe May. 11 at 9:39 PM

$KAPA My 200k plus shares are long term bullish. Certainly plan to vote yes for r/s. Plan to vote no for increasing executive compensation.

2 · Reply

uptrend2025 May. 11 at 9:09 PM

$KAPA Pending top 5 catalysts: 1. Q1 2026 Earnings / 10-Q Filing 2. Celyn / CL-273 Transaction Closing 3. CL-273 First-in-Human Trial Initiation 4. ENV105 Phase 2 Prostate Cancer Interim / Updated Data 5. ENV105 Phase 1 NSCLC updates

0 · Reply

TraderBuckNKY May. 11 at 8:38 PM

$KAPA does the "Right to Try" Act affect this at all?... (it got some press today...)

0 · Reply

ezcheezie May. 11 at 7:11 PM

$KAPA Looks like we'll be voting on R/S.

0 · Reply

Xtracked May. 11 at 2:32 PM

$KAPA Someone dumped their shares today. It is as if they want investors to leave. WTF is management up to? We have bled enough already

1 · Reply

uptrend2025 May. 8 at 9:12 PM

$KAPA I am loading KAPA. Earnings deadline Friday, May 15nth. They could do release before or they can extend another 5 days.

0 · Reply

Oldshoe May. 8 at 8:36 PM

$KAPA Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026.

0 · Reply

Xtracked May. 6 at 1:35 PM

$KAPA has a lot of pending news. Shareholder vote / closing/ IND / updates...plus Will they have to explain everything next week earnings, or will they ease the pressure w a PR in advance? Some fkry for sure

0 · Reply

uptrend2025 May. 5 at 10:53 PM

$KAPA Better days later this month and June 👀

2 · Reply

DipBuyInvester May. 5 at 4:37 PM

$KAPA What’s up $KAPA??!!

0 · Reply

TraderBuckNKY May. 4 at 2:31 PM

$KAPA ...did you mean this week...?

0 · Reply

Xtracked May. 4 at 2:05 PM

$KAPA IS THIS THE WEEK THAT KAPANATION IS FINALLY INFORMED?!? WILL WE SEE A SHIP ON THE HORIZON?!? SURVIVED THE PAST 7 MONTHS ON EXPECTATIONS & HOPIUM.... IT'S TIME

0 · Reply

Xtracked Apr. 30 at 1:35 PM

$KAPA Someone sucked those up immediately

0 · Reply

Market Cap	11.35M
Revenue (ttm)	0.00
Net Income (ttm)	-5.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	275,800
Avg Vol	127,164
Day's Range	N/A - N/A
Shares Out	21.41M
Stochastic %K	12%
Beta	1.51
Analysts	Strong Sell
Price Target	$8.33